Latest news and releases
Herantis Pharma Plc commences a directed share issue, contemplates secondary listing on Nasdaq First North Growth Market Sweden and expands its management team
Read moreHerantis Pharma publishes newsletter for September-October
Read moreHerantis Pharma Plc Provides Update on Timeline for Ongoing Phase 1-2 CDNF Trial
Patient recruitment has been completed and the medical device used in injecting CDNF has been implanted in 17 patients with Parkinson's. The trial continues to proceed as anticipated.
Read moreHerantis Pharma publishes newsletter for July-August
We were honored to participate in the Neurotrophic factors and Parkinson’s meeting. Dr. Hartiala was awarded EURAP's best presentation when presenting our Lymfactin® clinical study in April....
Read moreHerantis Pharma Plc announces half year financial report January 1 – June 30, 2019 (unaudited)
The Company’s financial position in the last half-year period is solid. The company continues to discuss collaboration opportunities with potential partners for its drug development...
Read moreHerantis Pharma publishes newsletter for May-June
We shared our progress in the development of Lymfactin® with several key opinion leaders at the EURAPS 2019 meeting. Read also about our greetings from the Bio€quity meeting!
Read moreHerantis on Twitter
Blog posts
World Bioethics Day is a good day to learn about bioethics
Did you know that Bioethics is a very broad and challenging branch of science with potentially significant impact on our future?
Read moreHow to invest smartly in biotech?
The big difference in biotech investments compared to more established businesses is that you need to assess a possible future success rather than consider existing cash flow and profit.
Read moreArtificially intelligent drug development
Artificial intelligence (AI) will shape our world in the coming years. People already speculate how AI can superhumanly solve any human problem. What will its role be in healthcare?
Read moreThe price of life (and drugs)
Developing of novel drugs is always a high-risk endeavor and success should result in a financial reward. However, what is an acceptable cost for the treatment of severe rare disorders?
Read moreHow big is big: The economic burden of disease
The global direct healthcare costs are approaching $10 trillion. What does that signify? The CEO gives a concrete example to elucidate the potential significance of our work.
Read moreBig Pharma and risk acceptance for true innovation
The development of new drugs is always risky. The more innovative an approach is the higher are the risks. For a real breakthrough in an unmet clinical need, high risk acceptance is needed.
Read more